A Multicenter, Single-Arm, Phase II Trial of Bevacizumab in Subjects With Platinum-Resistant Epithelial Carcinoma of the Ovary or Primary Peritoneal Carcinoma for Whom Subsequent Doxil or Topotecan Therapy Has Failed
Phase of Trial: Phase II
Latest Information Update: 22 May 2017
At a glance
- Drugs Bevacizumab (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Genentech
- 15 May 2007 Status changed from in progress to completed.
- 17 Aug 2005 New trial record.